Danone and Nestle have remained silent over reports that each company has submitted competing preliminary bids for Pfizer‘s baby food business.
According to a Bloomberg report, which cited two unnamed sources, Danone and Nestle have both offered around US$10bn for the business and are now looking at how to overcome antitrust hurdles.
Go deeper with GlobalData
Bloomberg suggested that Nestle is considering buying Pfizer wholesale and auctioning off businesses that would raise regulatory concerns, while Danone is reportedly weighing a joint bid with Mead Johnson Nutrition.
Danone and Nestle declined to comment on the reports.
Meanwhile, a spokesperson for drug-maker Pfizer told just-food that the group had yet to make a decision over the future of the unit, which generated revenues of $2.14bn last year.
“We are still exploring options,” the spokesperson said. “These could include – but are not limited to – a sale or spin-off of the business.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
